Get all your news in one place
100’s of premium titles. One news app. Zero ads. Just $10 per month.
Benzinga

4 Analysts Have This to Say About 10x Genomics

Analysts have provided the following ratings for 10x Genomics (NASDAQ:TXG) within the last quarter:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 2 1 1 0 0
Last 30D 0 1 0 0 0
1M Ago 1 0 1 0 0
2M Ago 0 0 0 0 0
3M Ago 1 0 0 0 0

In the last 3 months, 4 analysts have offered 12-month price targets for 10x Genomics. The company has an average price target of $108.75 with a high of $150.00 and a low of $85.00.

Below is a summary of how these 4 analysts rated 10x Genomics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

This current average has decreased by 21.62% from the previous average price target of $138.75.

Analyst Ratings: What Are They?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.